Top Page
Enlivex
(NASDAQ:ENLV)
Enlivex (ENLV) vs. SPDR S&P 500 ETF (SPY)
Enlivex Business Overview & Revenue Model
Enlivex Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Mar 2023 | Mar 2022 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.28M |
| Gross Profit | -292.00K | -545.00K | -835.00K | -777.00K | -546.00K | -286.00K |
| EBITDA | -13.67M | -14.47M | -28.22M | -25.02M | -18.74M | -9.50M |
| Net Income | -12.70M | -15.01M | -29.07M | -31.06M | -14.47M | -11.82M |
Balance Sheet | ||||||
| Total Assets | 20.94M | 27.69M | 36.83M | 67.64M | 95.15M | 40.36M |
| Cash, Cash Equivalents and Short-Term Investments | 18.32M | 23.61M | 27.32M | 48.12M | 84.13M | 35.71M |
| Total Debt | 701.00K | 534.00K | 1.03M | 4.85M | 617.00K | 203.00K |
| Total Liabilities | 3.46M | 4.10M | 6.75M | 10.80M | 10.11M | 4.87M |
| Stockholders Equity | 17.48M | 23.59M | 30.08M | 56.84M | 85.04M | 35.49M |
Cash Flow | ||||||
| Free Cash Flow | -12.33M | -13.11M | -23.76M | -32.08M | -19.17M | -12.03M |
| Operating Cash Flow | -12.23M | -13.01M | -23.52M | -23.95M | -17.54M | -11.01M |
| Investing Cash Flow | 11.78M | 9.06M | -25.97M | 62.52M | -38.41M | -20.98M |
| Financing Cash Flow | 1.84M | 6.45M | 360.00K | 150.00K | 60.98M | 33.08M |
Enlivex Technical Analysis
Enlivex Risk Analysis
Enlivex Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $268.24M | -2.12 | -57.64% | ― | ― | 46.09% | |
47 Neutral | $22.36M | -3.55 | ― | ― | ― | ― | |
46 Neutral | $3.71M | -0.08 | ― | ― | 26.20% | -42.26% | |
46 Neutral | $24.96M | -0.55 | -87.18% | ― | ― | 38.42% | |
42 Neutral | $7.50M | ― | -196.60% | ― | ― | ― |
Enlivex Corporate Events
On January 26, 2026, Enlivex announced that its primary digital treasury asset, the RAIN token, was listed on the WhiteBIT cryptocurrency exchange effective January 21, 2026, giving the token access to a major European and global trading venue. The move is intended to broaden market access and secondary liquidity for RAIN and strengthen the infrastructure around Enlivex’s digital asset treasury strategy, potentially enhancing visibility among crypto market participants while the company continues to advance its core immunotherapy pipeline targeting osteoarthritis.
The most recent analyst rating on (ENLV) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Enlivex stock, see the ENLV Stock Forecast page.
On January 23, 2026, Enlivex Therapeutics announced it has begun the process of voluntarily delisting its ordinary shares from the Tel Aviv Stock Exchange, with trading on the TASE expected to end on April 23, 2026 and the delisting to become effective around April 26, 2026. The company’s shares will continue to trade on the Nasdaq Capital Market under the ticker ENLV, and all shares currently traded in Tel Aviv can be transferred to Nasdaq. Enlivex’s board approved the move to concentrate trading exclusively in the U.S., citing the desire to operate under a single regulatory regime, cut duplicative administrative costs tied to dual listing, potentially boost liquidity on Nasdaq, and focus investor and public relations efforts on the U.S. capital markets, a shift that could streamline operations and sharpen its visibility among U.S. biotech and digital-asset-focused investors.
The most recent analyst rating on (ENLV) stock is a Hold with a $0.96 price target. To see the full list of analyst forecasts on Enlivex stock, see the ENLV Stock Forecast page.
On January 7, 2026, Enlivex Therapeutics announced that its primary digital treasury asset, the RAIN token, began trading on the KuCoin cryptocurrency exchange effective January 6, 2026, providing access to one of the world’s largest digital asset trading platforms and significantly broadening the token’s potential user base, particularly in Southeast Asia. By securing a listing on a major global venue known for deep retail liquidity, Enlivex aims to enhance market access and secondary liquidity for its RAIN holdings, marking a key milestone in its digital asset treasury strategy and underscoring the company’s dual positioning at the intersection of late-stage osteoarthritis drug development and emerging decentralized finance infrastructure.
The most recent analyst rating on (ENLV) stock is a Hold with a $0.72 price target. To see the full list of analyst forecasts on Enlivex stock, see the ENLV Stock Forecast page.
On December 18, 2025, Enlivex Therapeutics announced it will convene an Extraordinary General Meeting of Shareholders on February 3, 2026, at its offices in Ness Ziona, Israel, to seek investor approval for a series of significant corporate governance and capital structure changes. Shareholders will be asked to vote on amendments to the Articles of Association to change the company’s name to Enlivex Ltd. (or a similar name), introduce a classified board with three staggered director classes, and increase authorized share capital, as well as to approve updated exemption and indemnification agreements for directors and the CEO, an equity bonus in restricted share units for the executive chairman, and a reverse share split of ordinary shares at a ratio between 1-for-2 and 1-for-20 to be implemented within 12 months at the board’s discretion, moves that collectively signal a strategic effort to strengthen corporate defenses, enhance capital flexibility and address share price and listing considerations for stakeholders.
The most recent analyst rating on (ENLV) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Enlivex stock, see the ENLV Stock Forecast page.
On December 4, 2025, Enlivex Therapeutics announced a virtual fireside chat scheduled for December 11, 2025, to discuss its digital asset strategy and the clinical development of Allocetra™. The company recently secured a $212 million private placement, which will support its strategic initiatives. This announcement highlights Enlivex’s efforts to strengthen its market position through innovative financial strategies and continued focus on addressing the significant healthcare burden of osteoarthritis.
The most recent analyst rating on (ENLV) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Enlivex stock, see the ENLV Stock Forecast page.
On November 24, 2025, Enlivex Therapeutics Ltd. completed a $212 million private placement, marking a significant step in its strategic expansion into digital asset treasury operations through the RAIN token. The funds will support the company’s cryptocurrency treasury strategy and ongoing clinical development of Allocetra™. The appointment of Matteo Renzi, former Prime Minister of Italy, to the Board of Directors underscores Enlivex’s commitment to innovation and strategic leadership. Renzi’s expertise is expected to enhance the company’s positioning in both the biotech and digital asset sectors.
The most recent analyst rating on (ENLV) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Enlivex stock, see the ENLV Stock Forecast page.
Enlivex Therapeutics Ltd. announced positive six-month topline data from the Phase IIa stage of its Allocetra™ trial for moderate to severe knee osteoarthritis, reaffirming previous three-month results. The study demonstrated significant pain reduction and improved function in patients aged 60 and above, with sustained efficacy and a favorable safety profile, supporting further development and commercial potential.
The most recent analyst rating on (ENLV) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Enlivex stock, see the ENLV Stock Forecast page.
On November 24, 2025, Enlivex Therapeutics Ltd. announced the completion of a securities purchase agreement with accredited investors, resulting in a private placement of 212 million ordinary shares. The proceeds from this transaction will be used to implement a digital asset treasury strategy, primarily involving the acquisition of RAIN tokens and other digital assets. This move aims to support Enlivex’s operational needs and align its reserve management with the RAIN ecosystem development. The company has also entered into a Treasury Management Agreement with Elinnovation Labs Ltd. to manage these assets, highlighting a strategic shift towards cryptocurrency and digital asset management, which carries inherent risks due to market volatility and regulatory uncertainties.
The most recent analyst rating on (ENLV) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Enlivex stock, see the ENLV Stock Forecast page.
Enlivex Therapeutics Ltd. released its unaudited condensed consolidated financial statements for the periods ending September 30, 2025, and 2024. The financial report highlights a decrease in total assets from $27.7 million at the end of 2024 to $20.9 million by September 2025, alongside a net loss of $7.5 million for the nine months ending September 2025. This financial performance reflects ongoing challenges in the company’s operations, potentially impacting its market position and stakeholder confidence.
The most recent analyst rating on (ENLV) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Enlivex stock, see the ENLV Stock Forecast page.
On November 10, 2025, Enlivex Therapeutics Ltd. attempted to hold its Annual General Meeting of Shareholders but had to adjourn due to a lack of quorum. The meeting is rescheduled for November 17, 2025, with extended deadlines for shareholder voting, reflecting the company’s commitment to ensuring shareholder participation and governance compliance.
The most recent analyst rating on (ENLV) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Enlivex stock, see the ENLV Stock Forecast page.